Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined the current clinical practices for diagnosing and managing alopecia areata in Poland, finding that patient care is inadequate and falls short in using validated severity tools and providing access to advanced therapies despite the availability of new medications like Janus kinase inhibitors.

In this study, post-COVID-19 patients showed substantial multisystem symptoms six to eight months after infection compared to controls, with a higher burden in non-respiratory areas like fatigue and neurocognitive issues, despite respiratory symptoms largely resolving.

In this case study, researchers documented chronic dermatitis and ulcerative lesions in a 70-year-old Syrian man following chlorine gas exposure during the conflict, highlighting the need for healthcare planning and registries to manage long-term effects in affected populations.

In this study conducted at Afzalipour Hospital in Iran, researchers found a significant prevalence of alopecia, particularly resembling telogen effluvium, among COVID-19-recovered patients, with hair loss being more common in females and correlating with arterial oxygen saturation levels.

This meta-analysis of animal studies found that alkaloids have potential anti-influenza and anti-inflammatory effects, correlating with improved viral titers and survival rates, though they did not effectively reduce TNF-α and IL-6 levels. Extensive further studies are needed to confirm these findings before considering clinical application.

The authors propose that higher testosterone levels in hospitalized COVID-19 patients might be associated with worse outcomes.

This retrospective audit found that patients with alopecia areata often experience significant psychological distress, yet proper mental health assessments and referrals to support services are infrequently conducted, highlighting a gap between current practice and guideline recommendations for comprehensive care.

This study found that the STRIAA scoring tool provides a rapid and highly reliable assessment of alopecia areata severity, showing a significant correlation with the traditional SALT score, thus enhancing clinical evaluation in patients with this condition.

This study aims to assess the real-world effectiveness of baricitinib, a JAK inhibitor, for promoting regrowth of nasal, genital, and beard hair in patients with severe alopecia areata, expanding on findings from the BRAVE-AA clinical trial. Results are not reported.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

In this study, individuals with alopecia areata in the UK incurred significant costs for managing their condition, with those experiencing more severe symptoms and lower disposable income facing higher financial burdens.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

This study highlights the use of dermatoscopy as a valuable tool for diagnosing and monitoring alopecia areata, noting that specific hair shaft alterations such as exclamation-mark hairs and black dots are indicators of active disease, while vellus hairs signal early regrowth.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

This study identified three EDAR gene variants potentially linked to hypohidrotic ectodermal dysplasia in three Pakistani families, which could aid in genetic counseling for similar cases.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

Patients and doctors often disagree on alopecia areata severity and treatment satisfaction.

This study established consensus criteria for classifying alopecia areata severity, aiding clinicians in accurate diagnosis and treatment planning.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This review highlights the variability and unpredictability of alopecia areata, ranging from single scalp patches to total body hair loss, and notes the 2022 approval of the first AA-specific drug, baricitinib, potentially spurring new research into targeted treatments.

This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.